May 8, 2019 at 8:00PM BRT
About the Event: 
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors”.
In this one hour webinar, we will review and highlight the “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors“. We will discuss the updated guideline in terms of the evidence-based standards for clinical molecular testing of non-small cell lung cancers (NSCLC) that guide targeted therapy and treatment. We will identify where the guideline strengthens or reaffirms the 2013 recommendations for patients with lung adenocarcinoma, as well as recommendations for testing several new genes. The latest evidence supporting these new testing technologies and the anticipated impact on optimal patient care will be discussed.
Activity Objectives:
  • Inform and educate clinicians and other health care professionals on the revised Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors.
  • Review updated evidence and testing for new genes.
  • Provide a multi-disciplinary perspective of the use and benefit of molecular testing.
Following the presentation, there will be ample time for discussion and questions. Questions and comments can be submitted to Dr. Arcila and Dr. Dalurzo via internet chat. This event will not provide CME credit.
Event number: 665 116 700